WuXi STA passes first EMA drug product pre-approval inspection for Wuxi city site
The PAI focussed on the drug product manufacturing of an innovative drug for one of WuXi STA’s partners
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
WuXi STA’
WuXi STA launches maiden parenteral formulation manufacturing line
This wholly automatic sterile manufacturing line operates in a full isolation system with an annual capacity of two million units
WuXi STA passes first US FDA drug product pre-approval inspection at its Shanghai Waigaoqiao site
During the five-day inspection from 22nd to 26th October, 2021, the FDA inspector conducted a comprehensive onsite assessment,…
WuXi STA forms strategic partnership with Coherent Biopharma
According to the agreement, WuXi STA will become the preferred CDMO partner and provide Coherent Biopharma with integrated CMC…
WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland
The facility enhances WuXi STA's drug product capacity in Europe while better enabling global customers
WuXi STA’s Jinshan facility passes EMA inspection
In March, the company’s new drug product manufacturing facility in Shanghai Waigaoqiao passed its GMP inspection by the European…